Canada markets closed
  • S&P/TSX

    19,228.03
    -0.84 (-0.00%)
     
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • DOW

    33,800.60
    +297.03 (+0.89%)
     
  • CAD/USD

    0.7983
    +0.0022 (+0.28%)
     
  • CRUDE OIL

    59.34
    -0.26 (-0.44%)
     
  • BTC-CAD

    75,634.51
    +1,813.77 (+2.46%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • GOLD FUTURES

    1,744.10
    -14.10 (-0.80%)
     
  • RUSSELL 2000

    2,243.47
    +0.88 (+0.04%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • NASDAQ

    13,900.19
    +70.88 (+0.51%)
     
  • VOLATILITY

    16.69
    -0.26 (-1.53%)
     
  • FTSE

    6,915.75
    -26.47 (-0.38%)
     
  • NIKKEI 225

    29,768.06
    +59.08 (+0.20%)
     
  • CAD/EUR

    0.6704
    +0.0027 (+0.40%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 20, 2021 - IMVT

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - March 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Immunovant, Inc. (NASDAQ: IMVT) f/k/a Health Sciences Acquisitions Corporation (NASDAQ: HSAC) between October 2, 2019 and February 1, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get more information go to:

https://www.zlk.com/pslra-1/immunovant-inc-f-k-a-health-sciences-acquisitions-corporation-information-request-form?wire=5&prid=13187

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401's prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Immunovant, you have until April 20, 2021to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75958